- Georgiamune to ship preclinical solid tumor drug to Menarini in deal up to $1.1 billionGeorgiamune, a small biotech based in Maryland, announced that it will supply its preclinical solid tumor candidate to Menarini, a family‑owned pharmaceutical company in Italy. The agreement is st…
- Roche touts strong Phase 3 track record while trimming pipeline amid peer setbacksRoche's chief executive Thomas Schinecker highlighted the company's high success rate in Phase 3 trials, positioning it as a competitive advantage. The comment accompanied an announcement that Roc…